Carl Zeiss Meditec AG (ZEISS Medical Technology)

Carl Zeiss Meditec AG is a multinational medical technology company headquartered in Jena, Germany. The company's core business revolves around developing and providing innovative solutions for ophthalmology and microsurgery. Its mission is to drive progress, efficiency, and access to healthcare technology, supporting medical professionals in improving patients' quality of life.

The company operates primarily through two segments: Ophthalmic Devices and Microsurgery. The Ophthalmology segment offers a comprehensive portfolio including diagnostic and treatment systems for chronic eye diseases, surgical ophthalmology equipment, intraocular lenses for cataract surgery, and laser systems for vision correction. The Microsurgery segment provides visualization solutions and instruments for minimally invasive surgical treatments across neurosurgery, ENT, spine surgery, plastic and reconstructive surgery, and dentistry, alongside intraoperative radiotherapy. Carl Zeiss Meditec holds a leading market share in microsurgery and refractive laser surgery.

Carl Zeiss Meditec AG is publicly traded on the German stock exchange, listed on the TecDAX and SDAX, with Carl Zeiss AG holding approximately 59% of its shares. Maximilian Foerst was appointed President and CEO, effective June 1, 2025, with Justus Wehmer serving as CFO. Recent developments include a strategic collaboration with Envision Health Technologies Inc. in June 2026 to advance glaucoma care using virtual reality technology, and the 2024 acquisition of Dutch Ophthalmic Research Center (DORC) to strengthen its vitreoretinal surgery offerings.